DHR
Danaher Corporation
- Healthcare
- US companies in Healthcare (47)
- NYSE · USD
- Mkt cap $163.2bn
$232.00
as of 27 Oct 2026, 4% below its 52-week high
Screens as well placed to keep growing its dividend, though with some cut-risk signals worth watching. Its valuation looks somewhat extended against its own history.
These scores are a resilience check on the dividend, not a recommendation to buy or sell. They are not financial advice.
- Trailing yield
- 0.66%Last 12 months of regular payments at today's price
- Forward yield
- 0.74%Each payment expected in the next 12 months, not the latest one doubled
- Earnings cover
- 4.3×Pays 23% of earnings
- Cash cover
- 5.6×Free cash flow over dividends paid
- 5y dividend growth
- +12.2% a yearLast cut in FY2016
- Next ex-dividend date
- Estimated26 Dec 2026Quarterly dividend of about $0.36
Compared with US companies in Healthcare (47)
- Trailing yield is lower than 28 of the 46 other US companies in Healthcare.
- 5y dividend growth (as paid) is higher than 30 of the 38 other US companies in Healthcare with a 5y growth figure.
Quality
86
HighCapacity to keep growing the dividend
Risk
50
ModerateSignals of dividend-cut pressure
Trim
57
ModerateHow extended the valuation looks
Why Risk is 50
DHR against US companies in Healthcare (47)
Valuation against its own history
As of the last reported period (25 Sept 2026). P80 means the figure is higher than 80% of DHR’s past readings.
- P/E36.5×P65, neutral for this measure
- Yield0.69%P85, good for this measure
- FCF payout17.7%P100, poor for this measure
- Net debt / EBITDA2.94P92, poor for this measure
- DGR 5y+16.2%P63, neutral for this measure
- ROIC5.7%P32, neutral for this measure
Forecast your income with the DHR dividend calculator
Inspect surfaces history; it does not predict the future. Nothing here is financial advice or an instruction to buy or sell. Always do your own research. See the Terms of Service.